Skip to main content

Table 1 Subjects demonstration

From: Chronic cough and obstructive sleep apnoea in a sleep laboratory-based pulmonary practice

Characteristics OSA
n = 99
Non-OSA
n = 32
p-value
Age 52.2±11.6 48.3±13.1 0.105
Male, n (%) 75 (75.8) 17 (53.1) 0.025
BMI 28.9±4.1 24.9±4.3 0.000
Epworth Sleepiness Scale 12.9±4.5 12.8±5.5 0.884
Total AHI, /h 53.6±24.7 10.1±4.3 0.000
Pulmonary function test    
FEV1/FVC 83.7±8.4 82±12.5 0.394
FEV1 (% predicted) 82.6±20.1 82.6±17.5 0.993
FVC (% predicted) 82.4±17.9 86.8±22.3 0.278
Chronic cough 39 (39.4) 4 (12.5) 0.005
Upper airway cough syndrome 79 (79.8) 23 (71.9) 0.340
Gastro-esophageal reflux disease 43 (43.4) 5 (15.6) 0.006
Asthma 18 (18.2) 5 (15.6) 1.000
Medication    
Nasal steroid 72 (72.7) 20 (62.5) 0.276
Anti-histamine 79 (79.8) 23 (71.9) 0.340
ACEI or ARB 11 (11.1) 0 (0.0) 0.065
Inhaled corticosteroid 18 (18.2) 5 (15.6) 1.000
Long-acting β2 agonist 4 (4.0) 2 (6.2) 0.634
Proton pump inhibitor 43 (43.4) 5 (15.6) 0.006
  1. Data are presented as mean ± SD; BMI body mass index, FEV1 forced expiratory volume in one second, FVC forced volume capacity, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker.